Leerink Partners analyst Andrew Berens maintained a Buy rating on Aura Biosciences Inc on August 13 and set a price target of $22.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Berens has given his Buy rating due to a combination of factors that highlight Aura Biosciences Inc’s promising pipeline and strategic positioning. The company’s ongoing Phase 3 CoMpass trial for bel-sar in early-stage choroidal melanoma is progressing well, with over 240 patients registered in the pre-screening tool, indicating strong enrollment momentum. Aura Biosciences anticipates completing enrollment by the end of 2025, with trial results expected in 2027, which underscores the company’s commitment to advancing its clinical programs.
Additionally, Aura’s expansion of its choroidal metastases program to include various solid tumors in a basket study format reflects its innovative approach to cancer treatment. The company is also making strides in other ocular indications and non-muscle invasive bladder cancer, with data readouts expected in the coming years. With $177.3 million in cash reserves projected to support operations into the first half of 2027, Aura Biosciences is well-positioned financially to execute its strategic initiatives. These factors collectively contribute to Berens’s optimistic outlook and Buy rating for the stock.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AURA in relation to earlier this year.